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A Continuous Flow Method for the Desulfurization of Substituted 
Thioimidazoles Applied to the Synthesis of New Etomidate 
Derivatives 
Marcus Baumann,*[a] and Ian R. Baxendale[a] 
Abstract: A simple yet robust flow set-up for the efficient 
desulfurization of a series of thioimidazoles is presented generating 
the corresponding imidazole derivatives in high yields. The strategic 
choice of peristaltic over piston pumps allowed reliable delivery of the 
heterogeneous stream of thioimidazole substrate into a T-piece where 
it reacted with NaNO2 in the presence of acetic acid. This approach 
enabled the controlled and safe formation of the reactive nitrosonium 
species without uncontrolled exposure to hazardous nitrous oxide by-
products as observed in related batch protocols. The value of the 
resulting imidazole products was further demonstrated by their 
conversion into various esters representing new derivatives of the 
known analgesic etomidate via an efficient one pot Corey-Gilman-
Ganem oxidation procedure. 
Introduction 
Imidazoles are amongst the most prevalent bioactive heterocyclic 
entities and hence can be found not only in many natural products 
but also in numerous pharmaceutical and agrochemical agents.1 
Consequently, a considerable number of synthetic routes have 
been developed for their construction.2 Paramount to accessing 
structurally diverse imidazoles remains the availability of suitable 
building blocks that quickly furnish the desired target structures in 
high yield and selectivity. Addressing this requirement, we 
recently reported on an extension of the classical Marckwald 
multicomponent reaction which produces highly substituted 
thioimidazoles in a single step and makes use of diverse amine 
and carbohydrate building blocks (dihydroxyacetone, ketoses and 
aldoses) that are incorporated without erosion of stereochemical 
information (Scheme 1).3  
 
Scheme 1: Marckwald thioimidazole synthesis and structure or (R)-etomidate. 
 
Building on this work we wish to now report on a subsequent study 
that focuses on using these thioimidazoles as precursors for 
various imidazole products that hold promise as bioactive 
structures for example (R)-etomidate4 (Scheme 1). Essential to 
this endeavor is the development of an efficient process allowing 
desulfurization and hence expansion of the thioimidazole 
scaffolds. To render such a process more amenable to safe and 
efficient scale up we opted to harness the benefits of continuous 
flow chemistry as a valuable and well documented enabling 
technology. 
Results and Discussion 
With reliable access to diverse thioimidazole structures through 
the Marckwald reaction we initially surveyed the available 
literature for suitable methods to accomplish the desulfurization 
step. Amongst the methods reported two main options appeared 
attractive: (1) using a combination of hydrogen peroxide and a 
tungstic acid catalyst5 or (2) treating the thioimidazole substrates 
with aqueous sodium nitrite in glacial acetic acid6 (Scheme 2).  
 
Scheme 2: Selected methods for desulfurizing thioimidazoles. 
 
While the first method is interesting due to its green credentials, it 
was found that prolonged reaction times were needed to obtain 
full conversion of the substrate (8-14 h). Typically, this also 
required addition of further aliquots of both catalyst and hydrogen 
peroxide over time making this option less desirable. On the other 
hand, the second method is much faster (<1 h), yet requires 
cooling of the reaction mixture due to the reaction’s exothermic 
nature and additionally generates toxic nitrous oxide gases. 
Based on this pre-evaluation we decided to develop a flow 
process for the second method (NaNO2, glacial acetic acid) where 
we wished to harness the short reaction times and at the same 
time exploit the benefits of flow processing to mitigate risks 
associated with the exothermic nature of the reaction and the 
generation of toxic gases. Additionally, we wished to develop an 
efficient in-line quench process which would neutralize the acidic 
reaction mixture and gaseous by-products in a controlled manner. 
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For this purpose, we opted to use a Vapourtec E-series flow 
system7 which utilizes peristaltic rather than more traditional 
piston pumps to feed streams of substrates and reagents into the 
reactor modules. This decision was furthermore supported by the 
limited solubility of the Marckwald thioimidazoles, which although 
convenient for their isolation represents a challenge when utilizing 
them in further flow-based transformations. We thus suspended 
the desired thioimidazole substrates in a mixture of acetic acid 
and THF (0.5 M, 50:50 by volume, stream A) and using the 
peristaltic pumps mixed this with a second stream containing 
NaNO2 (2 M water, stream B) in a wide bore T-piece (Kinesis, 1.5 
mm i.d.)8 as depicted in Scheme 3. 
 
Scheme 3: Flow reactor set-up. 
 
To ensure consistent delivery of the thioimidazole suspension it 
was found that a short 5 cm length of tubing leading into the 
peristaltic pump was beneficial. This small adjustment together 
with vigorously stirring of the thioimidazole suspension allowed a 
smooth feed of the thioimidazole substrate showcasing how 
slurries can be processed in flow, a challenge that has seen 
considerable interest within the community.9 Upon mixing at the 
T-piece the combined reaction mixture became homogeneous 
indicating rapid formation of the key nitrosonium species and its 
reaction with the thioimidazole substrates. Passing the reaction 
mixture through a tubular flow coil (2 x 10 mL, 30 min residence 
time) at ambient temperature ensured quantitative conversion of 
all substrates into the desired imidazole products (Figure 1).  
 
Figure 1. Imidazoles 6a-j prepared via desulfurization in flow. 
 
Having established a quick and safe method for desulfurizing 
thioimidazoles in flow we decided to also incorporate an in-line 
quench to neutralize the acetic acid as well as gaseous products. 
This was accomplished by mixing a stream of aqueous ammonia 
(8 M) with the reaction stream using a standard T-piece. The 
reaction products were subsequently collected without passing a 
back-pressure regulator10 and isolated after aqueous extraction of 
the crude product stream yielding a series of imidazole products 
in high yield and purity. Crucially, it was found that this in-line 
quenching method not only neutralized the acetic acid, but more 
importantly eliminated any nitrous oxide by-products that are 
otherwise generated during this process. In light of this we 
propose a mechanism in which unreacted nitrosonium species 
will react with ammonia in a diazotization reaction that will 
generate benign nitrogen gas as the by-product (Scheme 4).11 
 
Scheme 4: Simplified mechanism for decomposing nitrous oxide by-products. 
 
Pleasingly, it was found that the functional groups on the 
imidazole core such as the hydroxymethyl moiety as well as 
several substituted aryl and alkyl appendages are tolerated under 
the reaction conditions. In addition, this simple flow set-up was 
found to allow for successful scale-up generating multigram 
quantities of several substrates such as 6a, 6c and 6f in 
equivalent yields with a typical productivity of ~10 mmol/h. 
Having accomplished the safe and efficient desulfurization of an 
array of thioimidazoles we next opted to evaluate their oxidative 
transformation into different ester products. To this end we 
exploited imidazoles 6 that upon oxidation of the hydroxymethyl 
group to an acid and subsequent ester formation render 
etomidate and various derivatives4 (Scheme 5).  
 
Scheme 5: Oxidation-esterification strategy to access etomidate derivatives. 
 
Although this oxidation and esterification sequence appears a 
straightforward process we anticipated the need for carefully 
selection of the reaction conditions as several standard oxidation 
procedures could affect the imidazole core or the reactive benzylic 
moiety. Furthermore, we were aware that the generation and 
isolation of the intermediate imidazole carboxylic acid might be 
cumbersome due to its polarity that would prohibit simple aqueous 
work-ups.    
 
It was quickly established that several oxidation methods 
including Swern-type, TEMPO and MnO2 do indeed generate the 
desired aldehyde derivative of our substrates, which under 
appropriate conditions can be further oxidized to the carboxylic 
acid species in a one-pot procedure (e.g. via TEMPO/BAIB)12. 
However, the latter process turned out to be less desirable as it 
required prolonged reaction times (10-18 h) and extra care when 
isolating the carboxylic acid due to its polarity. Instead of 
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optimizing this procedure we therefore opted to employ a less 
frequently exploited strategy for converting an alcohol substrate 
directly to an ester product based on the Corey-Gilman-Ganem13 
oxidation reaction. In this transformation, an activated alcohol is 
first oxidized with excess MnO2 to the corresponding aldehyde 
that then reacts in situ with cyanide allowing for subsequent 
oxidation of the resulting cyanohydrin to a cyano ketone that is 
finally trapped as an ester upon reaction with an alcohol 
nucleophile (Scheme 6).  
This approach not only mitigates isolation of any intermediate, but 
more importantly yields various ester products in a simple one-pot 
process. The desired structures (7a-n, Scheme 6) were isolated 
in good to excellent yields after conventional work-up and 
purification and include not only (R)- and (S)-etomidate but also 
various analogues possessing unprecedented substitution 
patterns on the aryl ring which we hope to evaluate for their 
analgesic properties in due course.  
 
Scheme 6: Batch synthesis of etomidate derivatives. 
 
In order to more efficiently isolate these ester products (7a-n) and 
at the same time decrease the risk of exposure to cyanide we 
opted to develop a final flow-based procedure trapping the used 
cyanide on an ion-exchange resin (Scheme 7).  
 
Scheme 7: Improved continuous isolation of ester products 7a-n. 
 
 
 
To this end triethylamine (1 equiv.) and chloroform (10 mL) were 
added to the crude reaction mixture at ambient temperature. 
Mixing was stopped and the MnO2 suspension allowed to settle. 
The supernatant was then pumped from the flask (1 mL/min) and 
directed into a glass column containing a small plug of silica (~2 
g) and Amberlite IRA-900 resin (chloride form, 10 equiv., ambient 
temperature). To minimise aspirating MnO2 particles the inlet 
tubing was covered with a microporous fritted filter. Upon passing 
through this column residual cyanide was exchanged for benign 
chloride that was subsequently removed by silica column 
chromatography allowing isolation of the desired products in very 
good yield and purity as before. Although not exploited in this 
instance, through this amendment the MnO2 slurry could also be 
recovered for re-use which would be especially worthwhile at 
larger scale as it allows to redefine this batch set-up as a 
continuously stirred tank reactor (CSTR), which could be utilized 
in sequential batch operations. 
Conclusions 
In summary, we have developed a simple flow process for the 
efficient desulfurization of a number of thioimidazoles furnishing 
the corresponding imidazole derivatives in high yield and purity. 
By utilizing peristaltic pumps our approach demonstrates the 
reliable and accurate delivery of the substrate as a suspension 
that reacts with sodium nitrite in the presence of acetic acid as co-
solvent prior to an in-line quench. Crucially, this flow strategy 
mitigates the need to perform this transformation at low 
temperature and at the same time does not liberate excessive 
amounts of toxic nitrous oxide by-products as observed in batch. 
Finally, we demonstrated the value of the generated imidazole 
products by their conversion into various analogues of the 
etomidate analgesic for which we exploited an efficient one-step 
Corey-Gilman-Ganem oxidation process in batch mode. 
Experimental Section 
All solvents, substrates and reagents were used as purchased without 
further purification. 1H-NMR spectra were recorded on 400 MHz 
instruments and are reported relative to residual solvent: CHCl3 (δ 7.26 
ppm) or d6-DMSO (2.50 ppm). 13C-NMR spectra were recorded on the 
same instruments and are reported relative to CHCl3 (δ 77.16 ppm) or d6-
DMSO (39.52 ppm). Data for 1H-NMR are reported as follows: chemical 
shift (δ/ ppm) (integration, multiplicity, coupling constant (Hz)). 
Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, m = multiplet, br. s = broad singlet, app = apparent. 
Data for 13C-NMR are reported in terms of chemical shift (δ/ ppm) and 
multiplicity (C, CH, CH2 or CH3). Data for 19F-NMR were recorded on the 
above instruments at a frequency of 376 MHz using CFCl3 as external 
standard. DEPT-135, COSY, HSQC, HMBC and NOESY experiments 
were used in the structural assignment. IR spectra were recorded neat 
(ATR sampling) with the intensities of the characteristic signals being 
reported as weak (w, <20% of tallest signal), medium (m, 21-70% of tallest 
signal) or strong (s, >71% of tallest signal). Low and high resolution mass 
spectrometry was performed using the indicated techniques on 
instruments equipped with Acquity UPLC and a lock-mass electrospray ion 
source. For accurate mass measurements the deviation from the 
calculated formula is reported in ppm. Melting points were recorded on an 
automated melting point system with a heating rate of 1 °C/min and are 
uncorrected.  
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General procedure for flow desulfurisation: 
Using a Vapourtec E-series flow system a vigourously stirred suspension 
of thioimidazole substrate 3 (0.5 M in HOAc/THF 50:50 by volume; 0.33 
mL/min) was directed into a wide bore T-piece (Kinesis, 1.5 mm i.d.) where 
it was combined with a solution of sodium nitrite (2 M, water; 0.33 mL/min). 
Upon uniting both streams the heterogeneous mixture quickly became 
homogeneous and generated gaseous by-products. This mixture was then 
directed into two flow coils (10 mL each, room temperature) giving a 
residence time of about 30 min. Using a further T-piece a solution of 
ammonium hydroxide (8 M, water; 0.5 mL/min) was added to the crude 
reaction mixture. Upon passing a further segment of tubing (~15 cm) the 
crude mixture was collected in a flask. After partitioning between EtOAc 
and water the desired product was obtained after drying (Na2SO4) and 
evaporating the organic layer.  
(1-Benzyl-1H)-imidazol-5-yl)methanol 6a 
Off-white solid. Yield: 90%. 1H-NMR (400 MHz, d6-DMSO) δ/ppm: 7.69 (d, 
J = 0.9 Hz, 1H), 7.32-7.38 (m, 2H), 7.26-7.32 (m, 1H), 7.17 (d, J = 6.9 Hz, 
2H), 6.83 (s, 1H), 5.24 (s, 2H), 5.14 (t, J = 4.5 Hz, 1H), 4.32 (d, J = 4.5 Hz, 
2H). 13C-NMR (101 MHz, d6-DMSO) δ/ppm: 138.9 (CH), 138.1 (C), 132.1 
(C), 129.1 (2CH), 128.0 (CH), 127.9 (CH), 127.5 (2CH), 53.3 (CH2), 48.0 
(CH2). IR (neat, ν/cm-1): 3182 (br m), 2947 (m), 2868 (m), 1457 (m), 1439 
(m), 1356 (m), 1248 (m), 1209 (m), 1103 (s), 1017 (s), 968 (m), 926 (m), 
835 (s), 715 (s), 656 (m). HR-MS (TQF+) calculated for C11H13N2O 
189.1028, found 189.1028. 
(1-(4-Bromobenzyl)-1H)-imidazol-5-yl)methanol 6b 
Off-white solid. Melting range: 136.0-138.1 °C. Yield: 87%. 1H-NMR (400 
MHz, d6-DMSO) δ/ppm: 7.71 (s, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 
8.0 Hz, 2H), 6.85 (s, 1H), 5.22 (s, 2H), 5.19 (br s, 1H), 4.33 (s, 2H). 13C-
NMR (101 MHz, d6-DMSO) δ/ppm: 139.0 (CH), 137.5 (C), 132.1 (C), 132.0 
(2CH), 129.7 (2CH), 128.0 (CH), 121.1 (C), 53.2 (CH2), 47.4 (CH2). IR 
(neat, ν/cm-1): 3238 (m), 3111 (m), 2946 (m), 1488 (s), 1435 (m), 1247 (m), 
1101 (m), 1073 (m), 1011 (s), 966 (m), 920 (m), 837 (s), 804 (s), 763 (m), 
733 (s), 669 (m). HR-MS (TQF+) calculated for C11H12N2OBr 267.0133, 
found 267.0122. 
(1-(2,4-Dichlorobenzyl)-1H)-imidazol-5-yl)methanol 6c 
Off-white solid. Melting range: 144.2-146.8 °C. Yield: 83%. 1H-NMR (400 
MHz, d6-DMSO) δ/ppm: 7.49 (s, 1H), 7.42 (d, J = 2.3 Hz, 1H), 7.20 (dd, J 
= 8.3, 2.3 Hz, 1H), 6.87 (s, 1H), 6.72 (d, J = 8.3 Hz, 1H), 5.29 (s, 2H), 5.11 
(br s, 1H), 4.37 (s, 2H). 13C-NMR (101 MHz, d6-DMSO) δ/ppm: 138.8 (CH), 
133.9 (C), 133.8 (C), 133.2 (C), 132.0 (C), 129.6 (CH), 129.2 (CH), 128.1 
(CH), 127.7 (CH), 53.4 (CH2), 45.7 (CH2). IR (neat, ν/cm-1): 3070 (br m), 
1589 (w), 1563 (w), 1504 (m), 1477 (m), 1401 (m), 1318 (m), 1241 (m), 
1103 (s), 1027 (s), 925 (s), 887 (m), 925 (s), 857 (m), 827 (s), 778 (s), 732 
(m), 653 (s). HR-MS (TQF+) calculated for C11H11N2OCl2 257.0248, found 
257.0242. 
(1-(2,6-Difluorobenzyl)-1H)-imidazol-5-yl)methanol 6d 
Off-white solid. Yield: 91%. 1H-NMR (400 MHz, d6-DMSO) δ/ppm: 7.52 (s, 
1H), 7.45-7.50 (m, 1H), 7.16 (app t, J = 8.2 Hz, 2H), 6.79 (s, 1H), 5.30 (s, 
2H), 5.14 (s, 1H), 4.44 (s, 2H). 13C-NMR (101 MHz, d6-DMSO) δ/ppm: 
161.2 (2CF, dd, J = 249, 8 Hz), 138.5 (CH), 132.1 (C), 131.7 (CH, t, J = 11 
Hz), 127.6 (CH), 112.8 (C, t, J = 19 Hz), 112.4 (2CH, m), 53.1 (CH2), 36.3 
(CH2, t, J = 4 Hz). 19F-NMR (367 MHz, d6-DMSO) δ/ppm: -114.5.  IR (neat, 
ν/cm-1): 3094 (br m), 2828 (m), 1624 (m), 1591 (m), 1505 (m), 1468 (s), 
1451 (m), 1360 (m), 1273 (m), 1255 (m), 1235 (m), 1212 (m), 1112 (m), 
1029 (s), 1017 (s), 933 (m), 833 (s), 793 (s), 767 (s), 677 (s), 660 (s), 533 
(m). HR-MS (TQF+) calculated for C11H11N2OF2 225.0839, found 
225.0841. 
(1-(3,5-bis-(Trifluoromethyl)benzyl)-1H)-imidazol-5-yl)methanol 6e 
Off-white solid. Melting range: 102.3-105.0 °C. Yield: 85%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.82 (s, 1H), 7.59 (s, 2H), 7.46 (s, 1H), 6.88 (s, 1H), 
5.38 (2H), 4.50 (s, 2H), 3.77 (br s, 1H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 
139.1 (C), 138.5 (CH), 132.4 (2C, q, J = 34 Hz), 131.4 (C), 128.6 (CH), 
127.2 (2CH, m), 122.9 (2CF3, q, J = 274 Hz), 120.2 (CH, m), 54.0 (CH2), 
47.9 (CH2). 19F-NMR (367 MHz, CDCl3) δ/ppm: -63.0.  IR (neat, ν/cm-1): 
3150 (br m), 1500 (w), 1379 (w), 1350 (w), 1275 (s), 1169 (s), 1124 (s), 
1021 (m), 910 (m), 844 (m), 704 (m), 682 (s), 661 (m). HR-MS (TQF+) 
calculated for C13H11N2OF6 325.0776, found 325.0775. 
1-[(1S)-1-Phenylethyl]-5-hydroxymethylimidazole 6f 
Beige solid. Melting range: 110.6-112.3 °C. Yield: 87%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.63 (d, J = 1.0 Hz, 1H), 7.24-7.36 (m, 3H), 7.08-7.13 
(m, 2H), 6.93 (s, 1H), 5.61 (q, J = 7.1 Hz, 1H), 4.51 (d, J = 13.5 Hz, 1H), 
4.34 (d, J = 13.5 Hz, 1H), 2.79 (br s, 1H), 1.86 (d, J = 7.1 Hz, 3H). 13C-
NMR (101 MHz, CDCl3) δ/ppm: 141.7 (C), 136.2 (CH), 131.2 (C), 129.0 
(2CH), 128.7 (CH), 127.9 (CH), 125.8 (2CH), 54.8 (CH), 54.4 (CH2), 22.5 
(CH3). IR (neat, ν/cm-1): 3090 (m), 2990 (m), 2843 (m), 1497 (m), 1450 
(m), 1323 (m), 1236 (m), 1212 (m), 1110 (m), 1020 (s), 931 (s), 867 (m), 
821 (m), 706 (s), 667 (s). HR-MS (TQF+) calculated for C12H15N2O 
203.1184, found 203.1184. 
1-[(1R)-1-Phenylethyl]-5-hydroxymethylimidazole 6g 
Beige solid. Melting range: 111.0-112.8 °C. Yield: 84%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.69 (d, J = 1.0 Hz, 1H), 7.27-7.37 (m, 3H), 7.08-7.12 
(m, 2H), 7.00 (s, 1H), 5.60 (q, J = 7.1 Hz, 1H), 4.53 (d, J = 13.4 Hz, 1H), 
4.35 (d, J = 13.4 Hz, 1H), 1.88 (d, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3) δ/ppm: 141.8 (C), 136.4 (CH), 130.9 (C), 129.1 (CH), 129.0 (2CH), 
128.0 (CH), 125.7 (2CH), 54.8 (CH), 54.6 (CH2), 22.5 (CH3). IR (neat, ν/cm-
1): 3090 (m), 2989 (m), 2841 (m), 1497 (m), 1450 (m), 1323 (m), 1236 (m), 
1212 (m), 1110 (m), 1020 (s), 931 (s), 867 (m), 821 (m), 788 (m), 743 (m), 
705 (s), 667 (s). HR-MS (TQF+) calculated for C12H15N2O 203.1184, found 
203.1186. 
(1-Butyl-1H)-imidazol-5-yl)methanol 6h 
Off-white solid. Yield: 93%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.19 (s, 
1H), 6.61 (s, 1H), 6.38 (br s, 1H), 4.44 (s, 2H), 3.84 (t, J = 7.4 Hz, 2H), 
1.56-1.66 (m, 2H), 1.18 (app hex, J = 7.4 Hz, 2H), 0.78 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3) δ/ppm: 137.3 (CH), 131.7 (C), 127.0 (CH), 
53.2 (CH2), 44.8 (CH2), 32.8 (CH2), 19.8 (CH2), 13.5 (CH3). IR (neat, ν/cm-
1): 3171 (br s), 2958 (s), 2873 (s), 1503 (s), 1460 (m), 1368 (m), 1251 (m), 
1211 (m), 1111 (s), 1021 (s), 926 (m), 822 (s), 758 (m), 663 (s). HR-MS 
(TQF+) calculated for C8H15N2O 155.1184, found 155.1193. 
(1-(2-Morpholinoethyl)-1H-imidazol-5-yl)methanol 6i 
Yellow oil. Yield: 82%. 1H-NMR (400 MHz, d4-MeOH) δ/ppm: 7.87 (d, J = 
1.0 Hz, 1H), 6.99 (s, 1H), 4.63 (s, 2H), 4.24 (app t, J = 6.1 Hz, 2H), 3.65-
3.73 (m, 4H), 2.78 (app t, J = 6.1 Hz, 2H), 2.50-2.57 (m, 4H). 13C-NMR 
(101 MHz, d4-MeOH) δ/ppm: 138.3 (CH), 131.8 (C), 125.6 (CH), 66.3 
(2CH2), 58.6 (CH2), 53.5 (2CH2), 52.5 (CH2), 42.0 (CH2). IR (neat, ν/cm-1): 
2900-3200 (broad), 2854 (w), 1707 (m), 1564 (m), 1453 (m), 1363 (m), 
1262 (s), 1112 (s), 1010 (s), 854 (m), 660 (m), 608 (m). HR-MS (TQF+) 
calculated for C10H18N3O2 212.1399, found 212.1392. 
(1-(2-(Cyclohex-1-en-1-yl)ethyl)-1H-imidazol-5-yl)methanol 6j 
Colourless oil. Yield: 80%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.33 (s, 1H), 
6.73 (s, 1H), 5.35 (br s, 1H), 4.56 (s, 2H), 4.26 (br s, 1H), 4.04 (app t, J = 
7.2 Hz, 2H), 2.36 (app t, J = 7.2 Hz, 2H), 1.85-1.97 (m, 4 H), 1.54-1.65 (m, 
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2 H), 1.43-1.52 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 137.9 (CH), 
133.5 (C), 131.3 (C), 127.6 (CH), 124.5 (CH), 53.8 (CH2), 43.9 (CH2), 39.2 
(CH2), 28.3 (CH2), 25.2 (CH2), 22.8 (CH2), 22.2 (CH2). IR (neat, ν/cm-1): 
3110 (broad, 2925 (m), 2835 (m), 1501 (m), 1437 (m), 1361 (m), 1110 (m), 
1019 (s), 919 (m), 820 (m), 728 (s), 661 (s). HR-MS (TQF+) calculated for 
C12H19N2O 207.1497, found 207.1474. 
General procedure for batch oxidation: 
To a solution of alcohol 6 in the desired alcohol solvent (0.3 M) was added 
MnO2 (40 equiv.), NaCN (0.5 equiv.) and acetic acid (2 drops). This mixture 
was heated at 80 °C until t.l.c. and 1H-NMR indicated complete conversion 
of the substrate into the desired ester species (typically 12 h). The reaction 
mixture was cooled to 25 °C and filtered over a pad of celite yielding the 
crude product after evaporation of the solvents. Final purification was 
accomplished by silica column chromatography using EtOAc/hexanes (10-
30% EtOAc) as eluent. 
Methyl 1-benzyl-1H-imidazole-5-carboxylate 7a 
Off-white solid. Yield: 78%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.76 (d, J 
= 1.0 Hz, 1H), 7.61 (s, 1H), 7.28-7.35 (m, 3H), 7.13-7.18 (m, 2H), 5.50 (s, 
2H), 3.80 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 160.6 (C), 142.2 
(CH), 138.0 (CH), 136.2 (C), 128.9 (2CH), 128.1 (CH), 127.3 (2CH), 122.5 
(C), 51.5 (CH3), 50.0 (CH2). IR (neat, ν/cm-1): 1709 (s), 1541 (m), 1436 
(m), 1363 (s), 1295 (m), 1222 (s), 1200 (m), 1107 (s), 918 (w), 809 (m), 
765 (m), 711 (s), 657 (s). HR-MS (TQF+) calculated for C12H13N2O2 
217.0977, found 217.0980. 
Ethyl 1-benzyl-1H-imidazole-5-carboxylate 7b 
Off-white solid. Melting range: 53.0-54.9 °C. Yield: 85%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.76 (d, J = 1.0 Hz, 1H), 7.60 (s, 1H), 7.25-7.33 (m, 
3H), 7.13-7.16 (m, 2H), 5.49 (s, 2H), 4.24 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 
7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 160.2 (C), 142.2 (CH), 
137.9 (CH), 136.3 (C), 128.9 (2CH), 128.1 (CH), 127.2 (2CH), 122.8 (C), 
60.5 (CH2), 50.0 (CH2), 14.2 (CH3). IR (neat, ν/cm-1): 2983 (w), 1708 (s), 
1539 (w), 1373 (m), 1293 (m), 1221 (s), 1124 (s), 1103 (s), 1019 (w), 921 
(w), 840 (w), 765 (m), 713 (s), 658 (m). HR-MS (TQF+) calculated for 
C13H15N2O2 231.1134, found 231.1132. 
Isopropyl 1-benzyl-1H-imidazole-5-carboxylate 7c 
Off-white solid. Yield: 81%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.76 (d, J 
= 1.0 Hz, 1H), 7.59 (s, 1H), 7.27-7.39 (m, 3H), 7.14-7.18 (m, 2H), 5.51 (s, 
2H), 5.14 (sept, J = 6.3 Hz, 1H), 1.28 (d, J = 6.3 Hz, 6H). 13C-NMR (101 
MHz, CDCl3) δ/ppm: 159.8 (C), 142.0 (CH), 137.8 (CH), 136.3 (C), 128.9 
(2CH), 128.1 (CH), 127.2 (2CH), 123.2 (C), 68.2 (CH), 50.1 (CH2), 21.9 
(2CH3). IR (neat, ν/cm-1): 2983 (w), 1708 (s), 1543 (w), 1459 (w), 1374 (s), 
1294 (w), 1225 (s), 1124 (m), 1100 (s), 715 (m), 657 (w). HR-MS (TQF+) 
calculated for C14H17N2O2 245.1290, found 245.1262. 
Ethyl 1-(2,6-difluorobenzyl)-1H-imidazole-5-carboxylate 7d 
Off-white solid. Yield: 80%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.72 (d, J 
= 1.0 Hz, 1H), 7.50 (s, 1H), 7.32 (app tt, J = 8.4, 6.5 Hz, 1H), 6.93 (dd, 8.4, 
J = 7.6 Hz, 2H), 5.63 (s, 2H), 4.33 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 
3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 161.4 (2CF, dd, J = 252, 7 Hz), 
160.3 (C), 141.7 (CH), 137.5 (CH), 131.1 (CH, t, J = 10 Hz), 122.9 (C), 
111.7 (2CH, m), 111.5 (C, m), 60.6 (CH2), 38.0 (CH2), 14.3 (CH3). 19F-NMR 
(376 MHz, CDCl3) δ/ppm: -114.0.  IR (neat, ν/cm-1): 2984 (w), 1710 (s), 
1627 (m), 1471 (s), 1374 (m), 1351 (m), 1220 (s), 1101 (s), 1025 (s), 902 
(w), 834 (m), 792 (s), 763 (m), 655 (s). HR-MS (TQF+) calculated for 
C13H13N2O2F2 267.0945, found 267.0949. 
2,2,2-Trifluoroethyl 1-(2,6-difluorobenzyl)-1H-imidazole-5-
carboxylate 7e 
Off-white solid. Yield: 77%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.83 (d, J 
= 1.0 Hz, 1 H), 7.58 (s, 1H), 7.35 (app tt, J = 8.5, 6.5 Hz, 1H), 6.95 (dd, J 
= 8.5, 6.5 Hz, 2H), 5.61 (s, 2H), 4.65 (q, J = 8.3 Hz, 2H). 13C-NMR (101 
MHz, CDCl3) δ/ppm: 161.4 (2CF, dd, J = 252, 7 Hz), 158.3 (C), 142.8 (CH), 
139.2 (CH), 131.2 (CH, t, J = 10 Hz), 122.9 (CF3, q, J = 277 Hz), 121.1 (C), 
111.7 (2CH, m), 111.3 (C, t, J = 19 Hz), 60.0 (CH2, q, J = 37 Hz), 38.1 
(CH2, t, J = 4 Hz). 19F-NMR (376 MHz, CDCl3) δ/ppm: -73.7, -114.0.  IR 
(neat, ν/cm-1): 1728 (s), 1628 (m), 1537 (m), 1472 (m), 1365 (m), 1273 (m), 
1219 (m), 1164 (s), 1102 (s), 1028 (m), 971 (m), 840 (m), 791 (m), 757 
(m), 651 (s). HR-MS (TQF+) calculated for C13H10N2O2F5 321.0662, found 
321.0665. 
Ethyl 1-(2,4-dichlorobenzyl)-1H-imidazole-5-carboxylate 7f 
Off-white solid. Melting range: 90.5-91.6 °C. Yield: 87%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.76 (d, J = 1.0 Hz, 1H), 7.61 (d, J = 1.0 Hz, 1H), 7.37 
(d, J = 2.1 Hz, 1H), 7.12 (dd, J = 8.4, 2.1 Hz, 1H), 6.70 (dd, J = 8.4, 0.8 Hz, 
1H), 5.53 (s, 2H), 4.22 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C-
NMR (101 MHz, CDCl3) δ/ppm: 160.0 (C), 142.4 (CH), 138.0 (CH), 134.9 
(C), 133.3 (C), 133.0 (C), 129.5 (CH), 129.0 (CH), 127.6 (CH), 122.7 (C), 
60.7 (CH2), 47.2 (CH2), 14.2 (CH3). IR (neat, ν/cm-1): 3097 (w), 2993 (w), 
1698 (s), 1541 (m), 1470 (m), 1373 (s), 1347 (m), 1295 (m), 1264 (m), 
1234 (s), 1194 (m), 1121 (s), 1101 (s), 1047 (m), 1022 (m), 864 (m), 834 
(m), 817 (m), 766 (s), 658 (m). HR-MS (TQF+) calculated for 
C13H13N2O2Cl2 299.0354, found 299.0352. 
Methyl 1-(2,4-dichlorobenzyl)-1H-imidazole-5-carboxylate 7g 
Off-white solid. Melting range: 102.4-105.0 °C. Yield: 81%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.72 (d, J = 1.1 Hz, 1H), 7.60 (d, J = 1.1 Hz, 1H), 7.33 
(d, J = 2.1 Hz, 1H), 7.09 (dd, J = 8.3, 2.1 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 
5.51 (s, 2H), 3.73 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 160.4 (C), 
142.5 (CH), 138.1 (CH), 134.5 (C), 133.3 (C), 132.9 (C), 129.5 (CH), 129.0 
(CH), 127.6 (CH), 122.4 (C), 51.6 (CH3), 47.1 (CH2). IR (neat, ν/cm-1): 3024 
(w), 2963 (w), 1698 (s), 1532 (m), 1473 (m), 1426 (m), 1365 (s), 1298 (m), 
1262 (m), 1225 (s), 1196 (s), 1115 (s), 1047 (m), 953 (m), 831 (s), 771 (s), 
655 (s). HR-MS (TQF+) calculated for C12H11N2O2Cl2 285.0198, found 
285.0189. 
Ethyl 1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole-5-carboxylate 
7h 
Off-white solid. Melting range: 63.8-65.0 °C. Yield: 75%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.78 (m, 2H), 7.73 (s, 1H), 7.59 (s, 2H), 5.62 (s, 2H), 
4.24 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3) δ/ppm: 160.1 (C), 142.1 (CH), 139.1 (C), 138.3 (CH), 132.2 (2C, q, 
J = 34 Hz), 127.3 (2CH, m), 123.0 (2CF3, q, J = 274 Hz), 122.6 (C), 122.1 
(CH, dt, J = 8, 4 Hz), 60.8 (CH2), 49.0 (CH2), 14.1 (CH3). 19F-NMR (376 
MHz, CDCl3) δ/ppm: -63.0. IR (neat, ν/cm-1): 1711 (m), 1543 (w), 1477 (w), 
1376 (m), 1353 (m), 1276 (s), 1170 (s), 1123 (s), 905 (m), 843 (m), 704 
(m), 682 (m), 659 (m). HR-MS (TQF+) calculated for C15H13N2O2F6 
367.0881, found 367.0876. 
Ethyl 1-(4-bromobenzyl)-1H-imidazole-5-carboxylate 7i 
Off-white solid. Melting range: 66.5-68.9 °C. Yield: 84%. 1H-NMR (400 
MHz, CDCl3) δ/ppm: 7.74 (d, J = 1.0 Hz, 1H), 7.61 (s, 1H), 7.41 (d, J = 8.4 
Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 5.43 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 
1.28 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 160.1 (C), 
142.1 (CH), 138.0 (CH), 135.4 (C), 132.0 (2CH), 128.8 (2CH), 122.6 (C), 
122.0 (C), 60.6 (CH2), 49.4 (CH2), 14.2 (CH3). IR (neat, ν/cm-1): 3096 (w), 
2983 (w), 1700 (s), 1540 (m), 1487 (m), 1368 (m), 1343 (s), 1260 (m), 1227 
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(s), 1184 (m), 1105 (s), 1010 (m), 917 (m), 766 (m), 752 (m), 659 (m). HR-
MS (TQF+) calculated for C13H14N2O2Br 309.0239, found 309.0246. 
 (R)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate 7j 
Colourless Oil. Yield: 85%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.78 (d, J = 
1.1 Hz, 1H), 7.73 (s, 1H), 7.31-7.39 (m, 2H), 7.26-7.31 (m, 1H), 7.15-.22 
(m, 2H), 6.37 (q, J = 7.1 Hz, 1H), 4.19-4.34 (m, 2H), 1.87 (d, J = 7.1 Hz, 
3H), 1.32 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 160.3 
(C), 141.1 (C), 139.7 (CH), 138.0 (CH), 128.8 (2CH), 128.0 (CH), 126.2 
(2CH), 122.7 (C), 60.4 (CH2), 55.3 (CH), 22.2 (CH3), 14.3 (CH3). IR (neat, 
ν/cm-1): 2982 (w), 1709 (s), 1537 (w), 1451 (m), 1373 (m), 1347 (m), 1210 
(s), 1130 (s), 1107 (s), 1054 (m), 1028 (m), 921 (m), 764 (s), 699 (s), 658 
(s). HR-MS (TQF+) calculated for C14H17N2O2 245.1290, found 245.1281. 
(S)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate 7k 
Colourless Oil. Yield: 82%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.78 (d, J = 
1.1 Hz, 1H), 7.73 (s, 1H), 7.31-7.37 (m, 2H), 7.25-7.31 (m, 1H), 7.16-7.21 
(m, 2H), 6.37 (q, J = 7.1 Hz, 1H), 4.16-4.35 (m, 2H), 1.86 (d, J = 7.1 Hz, 
3H), 1.32 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 160.3 
(C), 141.2 (C), 139.7 (CH), 138.1 (CH), 128.8 (2CH), 128.0 (CH), 126.3 
(2CH), 122.6 (C), 60.4 (CH2), 55.3 (CH), 22.2 (CH3), 14.3 (CH3). IR (neat, 
ν/cm-1): 2983 (w), 1709 (s), 1537 (w), 1451 (m), 1373 (s), 1347 (s), 1209 
(s), 1130 (s), 1106 (s), 1054 (m), 1028 (m), 921 (m), 764 (s), 699 (s), 659 
(s). HR-MS (TQF+) calculated for C14H17N2O2 245.1290, found 245.1283. 
Isopropyl 1-butyl-1H-imidazole-5-carboxylate 7l 
Colourless oil. Yield: 90%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.67 (d, J = 
1.0 Hz, 1H), 7.52 (s, 1H), 5.15 (sept, J = 6.3 Hz, 1H), 4.24 (t, J = 7.3 Hz, 
2H), 1.72 (tt, J = 8.3, 6.7 Hz, 2H), 1.30 (d, J = 6.3 Hz, 6H), 1.24-1.29 (m, 
2H), 0.90 (t, J = 7.4 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 159.8 
(C), 141.7 (CH), 137.7 (CH), 122.8 (C), 68.0 (CH), 46.7 (CH2), 33.1 (CH2), 
21.9 (2CH3), 19.7 (CH2), 13.6 (CH3). IR (neat, ν/cm-1): 2961 (w), 1706 (s), 
1540 (m), 1468 (m), 1372 (s), 1300 (m), 1251 (m), 1220 (s), 1133 (s), 1094 
(s), 923 (m), 839 (m), 767 (m), 658 (m). HR-MS (TQF+) calculated for 
C11H19N2O2 211.1447, found 211.1444. 
Ethyl 1-butyl-1H-imidazole-5-carboxylate 7m 
Colourless oil. Yield: 88%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.68 (d, J = 
1.0 Hz, 1H), 7.53 (s, 1H), 4.20-4.31 (m, 4H), 1.72 (tt, J = 8.3, 6.8 Hz, 2H), 
1.32 (t, J = 7.1 Hz, 3H), 1.16-1.30 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C-
NMR (101 MHz, CDCl3) δ/ppm: 160.2 (C), 141.8 (CH), 137.9 (CH), 122.4 
(C), 60.4 (CH2), 46.7 (CH2), 33.1 (CH2), 19.7 (CH2), 14.3 (CH3), 13.5 (CH3). 
IR (neat, ν/cm-1): 2961 (m), 1711 (s), 1539 (m), 1478 (m), 1373 (s), 1349 
(s), 1250 (m), 1219 (s), 1131 (s), 1097 (s), 1019 (w), 921 (w), 766 (m), 658 
(s). HR-MS (TQF+) calculated for C10H17N2O2 197.1290, found 197.1287. 
Ethyl 1-(2-cyclohex-1-en-1-yl)ethyl)-1H-imidazole-5-carboxylate 7n 
Colourless Oil. Yield: 79%. 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.69 (d, J = 
1.1 Hz, 1H), 7.48 (s, 1H), 5.28 (br s, 1H), 4.32 (t, J = 7.0 Hz, 2H), 4.29 (q, 
J = 7.1 Hz, 2H), 2.33 (t, J = 7.0 Hz, 2H), 1.83-1.95 (m, 4 H), 1.55-1.64 (m, 
2 H), 1.45-1.52 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3) δ/ppm: 160.3 (C), 142.0 (CH), 137.8 (CH), 133.2 (C), 124.6 (CH), 
122.3 (C), 60.4 (CH2), 45.6 (CH2), 39.5 (CH2), 28.2 (CH2), 25.2 (CH2), 22.8 
(CH2), 22.2 (CH2), 14.3 (CH3). IR (neat, ν/cm-1): 2927 (m), 2857 (w), 1711 
(s), 1539 (m), 1478 (m), 1373 (m), 1350 (m), 1220 (s), 1124 (s), 1104 (s), 
1022 (m), 922 (m), 835 (w), 766 (m), 659 (m). HR-MS (TQF+) calculated 
for C14H21N2O2 249.1603, found 249.1613. 
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